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The  purpose  of  this  inves t iga t ion  was to compare  blood to luene levels in S p r a g u e -  
Dawley rats after  oral and inhalation administrat ion.  Groups  of  30 rats were dosed  by ga- 
vage with 86 .7 ,217 ,433 ,  or  867 mg toluene/kg body wt or exposed for up to 6 hr, 5 rats per 
exposure ,  to an  a tmosphere  of  either 200 or 1000 ppm toluene. Blood was sampled by 
cardiac puncture  f rom 5 rats in each of  the six dose groups at 0.5, 1.0, 2.0, 4.0, 6.0, and 24.0 
hr  after gavage dosing or the  beginning of the inhalation exposure .  Blood toluene levels 
were analyzed.  A four -parameter  model  was fitted to the blood toluene levels of  the orally 
dosed rats.  The  area  under  the curve generated by this model,  represent ing total blood 
toluene concent ra t ion  over  6 hr, was calculated and compared  to the area under  the blood 
toluene curve for the 6-hr inhalation exposure .  Integrated areas from the two routes  of  
exposure  were used for direct compar i son  o f  oral and inhalation exposures .  The  data  dem- 
ons t r a t e  tha t  gavage  dos ing  can  be used  to approx ima te  inhala t ion e x p o s u r e  to tol- 
uene.  © 1988 Academic Press, Inc. 
INTRODUCTION 
Human exposure to toluene results from its use in the industrial setting and 
from substance abuse (glue sniffing). These exposures have resulted in numerous 
effects including altered liver function, CNS changes (Hayden et  al. ,  1977), pe- 
ripheral neuropathies (Faillace and Guynn, 1976), and renal damage (O'Brien et  
al . ,  1971). In our laboratory, toluene given orally has been shown to cause inner 
ear sensory hair cell lesions and elevated brainstem auditory evoked response 
(BAER) thresholds in the mid-frequency regions of the cochlea corresponding to 
2 -8  kHz (Sullivan, 1986). In contrast to our results, studies performed by Pryor 
et  al. (1984) have shown that rats exposed to toluene via inhalation exhibited 
high-frequency hearing loss. The purpose of this investigation was to determine 
whether gavage dosing results in blood levels of toluene similar to those obtained 
during inhalation exposure. These two routes of toluene administration were in- 
vestigated in order to compare the results of experiments on toluene-induced oto- 
toxicity from the oral and inhalation routes. 
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MATERIALS AND METHODS 
Chemicals. Analytical grade toluene, p-xylene, and carbon disulfide were pur- 
chased from Fisher Scientific Co. (Detroit, MI). 
Animals. A total of 210 male Sprague-Dawley rats (Charles River Laborato- 
ries, Inc., Portage, MI) were housed four per cage in metal cages and given water 
and rodent chow (Ralston-Purina Co.) ad libitum. The rats were allowed to be- 
come acclimated for at least 10 days before use. The average body weight for the 
rats at the time of use was 243 ___ 9 g (SD). 
Exposures. Groups of 30 rats were dosed by gavage with 86.7,217,433, or 867 
mg (0.10, 0.25, 0.50, or 1.0 ml) toluene/kg body wt or exposed for up to 6 hr to a 
toluene atmosphere of either 200 or 1000 ppm (3.76 mg toluene/m 3 air). Whole 
body inhalation exposures, 5 rats per concentration per exposure duration, were 
in 30-liter positive pressure exposure chambers. Chamber toluene concentrations 
were calibrated by sampling 1.0 ml of chamber air with a gas-tight syringe both 
before and during exposures and analyzing for toluene using the gas chromato- 
graphic method described below. Toluene atmosphere was generated by passing 
metered dilution air through a heated flask into which there was metered delivery 
of toluene liquid. The temperature of the chamber was monitored and used to 
calculate toluene concentrations. For gavage dosing, toluene was dissolved in 
corn oil and each treatment group received a total of 1.0 ml of dosing solution/kg 
body wt. Blood was sampled by cardiac puncture from 5 rats in each of the six 
dose groups at 0.5, 1.0, 2.0, 4.0, 6.0, and 24.0 hr after gavage dose or the begin- 
ning of the inhalation exposure, for a total of 30 rats per dose group. An addi- 
tional 30 rats, 5 per time point, served as controls. 
Toluene analysis. Toluene blood levels were analyzed using a method similar to 
that reported by Benignus et al. (1984b). Two 1.0-ml aliquots of blood from each 
rat were immediately added to 0.5 ml distilled/deionized water, vortexed, ex- 
tracted with 1.0 ml of CS2 containing a 10-ppm internal p-xylene standard, and 
vortexed again. The carbon disulfide layer was transferred by pipet into a capped 
3.0 glass vial and stored at 4°C until analysis. Blood toluene levels were analyzed 
by injecting an 2.0-1xl aliquot of CS2 into a Varian Model 3700 gas chromatograph 
fitted with a FID detector. The 6 foot x 1/4 in. i.d. glass column was packed with 
5% Bentone-34 and di-isodedocyl phthalate on 60/80 mesh diatoport solid sup- 
port. The carrier gas was N2 at 20 ml/min. The column temperature was 100°C 
and the injector and detector temperatures were 220°C. The attenuation settings 
were 2 x 10-1° and the chart speed was 1 cm/min. At these conditions, p-xylene 
and toluene had retention times of 2.8 and 4.8 min, respectively. Individual blood 
levels, ppm (mg/liter), were calculated using the ratio of the internal standard 10 
ppm p-xylene peak to the toluene peak. Final concentrations are reported as the 
average of the two samples. The limit of detection was 0.01 ppm. Method valida- 
tion included the analysis of both spiked and unspiked control blood to quantitate 
recovery and any background interferences. Any samples for which internal xy- 
lene recovery was below 60%, as determined by standard calibration curves, 
were discarded. 
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FIG. 1. Blood toluene concentration measured during 6-hr inhalation exposure to 200 or 1000 ppm. 
Modeling. The toluene blood levels from the orally dosed rats were fitted to the 
four-parameter (P1, P2, P3, and P4) model, 
In(blood toluene, ppm) = (In P1)(ln dose, mg/kg) 
+ In(1 - e ( -  P2(time, rain)) 
- (P3 - (P4(ln dose, mg/kg))) (1) 
(Benignus et al., 1984a), using the BMDP statistical package for nonlinear regres- 
sion (Jennrich and Ralston, 1983). The area under the curves generated by this 
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FIG. 2. Blood toluene concentrations measured over 6 hr after gavage dosing with 86.7,217, 433, or 
867 mg toluene/kg body wt. Shaded areas of each curve indicate the durations of the 95% maximum 
toluene blood concentration for that dose. 
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FIG. 3. Plot of both ln(gavage dose) [Eq. (4)] and In(inhalation exposure level) [Eq. (2)] against 
In(calculated area under each respective curve). Dotted line shows comparison of 500 ppm inhalation 
exposure to 230 mg/kg gavage dose. 
was calculated by integration of the curves and compared to the area under the 
blood toluene curves for the 6-hr inhalation exposures. Integrated areas from the 
two routes of exposure were used for direct comparison of oral (mg/kg) and inha- 
lation (ppm) exposures. The intervals during which the blood toluene concentra- 
tions were at i>95% of their maximum level were calculated from the gavage dose 
data and compared to the inhalation generated steady-state blood toluene levels. 
RESULTS 
Toluene blood levels during the 6-hr inhalation exposures were consistent with 
the toluene blood level-inhalation concentration dose relationship reported by 
Benignus et al. (1984b). The data in Fig. 1 show that the steady-state toluene 
blood concentrations for the 200 and 1000 ppm (3.76 mg toluene/m 3 air) inhalation 
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Fro. 4. Plot of ln(gavage dose) against In(inhalation exposure level) [Eq. (5)]. 
68  S U L L I V A N  A N D  C O N O L L Y  
concentrations were reached in both exposure levels within 30 rain. Plotting 
In(calculated area under these two curves) against In(inhalation dose, ppm) re- 
sults in the inhalation line in Fig. 3 described by the equation 
In(inhalation dose, ppm) = (1.901 In(area)) - 0.785. (2) 
The toluene blood levels from the four gavage dose levels are shown in Fig. 2 
(symbols) along with the model-generated predicted values (curves). Nonlinear 
regression analysis (Jennrich and Ralston, 1983) of the data results in the fol- 
lowing equation based on the model in Eq. (1): 
In(blood toluene, ppm) = (In 2.78)(ln dose, mg/kg) 
+ In(1 - e (-- 0.008(time, rain)) 
- (0.015-(0.0015(ln dose, mg/kg))). (3) 
The R ~ for Eq. (3) using the data from all four dose levels is 0.80. Plotting the 
In(calculated area under these four curves) against the In(oral dose (mg/kg)) re- 
sults in the gavage line in Fig. 3 described by the equation 
In dose (mg/kg) = 1.386(1n area) - 10.22. (4) 
DISCUSSION 
The 6-hr blood profiles from the oral toluene doses (Fig. 2) show several pat- 
terns. The peak blood toluene concentration increases with increasing dose. The 
shape of the curve flattens out with increasing dose, as indicated by lengthening 
durations of 95% maximum concentration times. The data show that blood pro- 
files from higher oral doses of 433 and 867 mg toluene/kg body wt more closely 
approximate the steady-state inhalation blood profiles than do the lower oral 
doses of 86.7 and 217 mg toluene/kg body wt. At 24 hr, blood toluene levels from 
all doses by both routes are at or below minimal detection levels. This indicates 
that toluene carryover from day to day is minimal. 
Figure 3 allows direct comparison of toluene blood levels after 6-hr inhalation 
exposure and after garage dosing. For example, a 6-hr 500 ppm toluene exposure 
has a blood toluene × time level equivalent to that of a 230 mg toluene/kg body 
wt dose. Combining Eqs. (2) and (4) by first solving for In(area) and then equating 
T AB L E  ! 
MODEL PARAMETERS AND R 2 VALUES FOR GAVAGE AND SUBCUTANEOUS DOSING 
Parameters  a R 2b 
Pl P2 P3 P4 Garage  Subcu taneous  
1 c 2.78 0.008 0.015 0.0015 0.80 N/A 
2 a 1.58 0.016 0.008 0.0012 0.58 0.74 
Parameters  (P1, P2, P3, and P4) f rom Eq. (1). 
b R 2 is the measu re  of fit of  data  to model.  
c Ga rage  dosing (this experiment) .  
d Subcu taneous  dosing (Benignus et  al. ,  1984a). 
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generates the following equation (Fig. 4), which describes the relationship be- 
tween the two routes: 
ln(gavage dose, mg/kg) = 1.27 In(inhalation dose, ppm) - 9.22. (5) 
The parameters in Eq. (3), which describe orally dosed toluene blood levels, 
can be compared to those reported for subcutaneous toluene dosing (Benginus et 
al., 1984). Table 1 shows the values of the four parameters and the respective R 2 
values for both oral and subcutaneous dosing. PI, describes the effect of the tol- 
uene dose level on the blood toluene level or the nonlinearlity of blood levels with 
increasing dose. P1 is greater for the oral route indicating a more linear effect of 
increasing dose on increasing blood concentration. P2 is a measure of uptake; P3 
and P4 are measures of elimination. The values for the parameters indicate that 
uptake is slower (P2) and elimination is faster (P3) for the gavage dosing com- 
pared to subcutaneous dosing. However, P4 (elimination) is not different between 
the two routes. When the blood toluene data from gavage dosing is fit to the 
model for subcutaneous dosing, R 2 decreases from 0.80 to 0.58. This suggests that 
the two routes (oral and subcutaneous) produce different blood toluene profiles. 
The results of this investigation show that a gavage dose of toluene which ap- 
proximates inhalation blood toluene levels can be calculated using Eq. (5). De- 
tailed analyses of the partition of toluene into various compartments, metabolism 
and elimination, as are done in pharmacokinetic studies, were not performed 
here. However, while elimination pathways would be the same for the two expo- 
sure routes, the data show that the rates of elimination were different. This is 
supported by the finding that P3, an elimination parameter in the blood profile 
model, is different for oral and subcutaneous routes. As the garage dose in- 
creases, the plateau phase of the blood-t ime concentration profiles from the ga- 
rage doses lengthen and better approximate the steady-state blood toluene con- 
centration during inhalation exposure. This limits the applicability of approxi- 
mating low-level inhalation of toluene with oral toluene administration. The 
gavage route has slower uptake and faster elimination than the subcutaneous 
route, which therefore has longer plateau phases than gavage dosing. This indi- 
cates that blood toluene levels after subcutaneous injection more closely approxi- 
mate blood levels during inhalation than do blood levels after gavage. This study 
shows that blood concentrations of toluene similar to those generated by a 6-hr 
inhalation exposure to 1000 ppm toluene can be achieved by gavage dosing. 
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